Apogee Therapeutics, Common Stock Net Income
| APGE Stock | 42.50 2.18 5.41% |
Apogee Therapeutics, Common fundamentals help investors to digest information that contributes to Apogee Therapeutics,'s financial success or failures. It also enables traders to predict the movement of Apogee Stock. The fundamental analysis module provides a way to measure Apogee Therapeutics,'s intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Apogee Therapeutics, stock.
| Last Reported | Projected for Next Year | ||
| Net Loss | -75.6 M | -79.4 M | |
| Net Loss | -75.6 M | -79.4 M | |
| Net Loss | (1.91) | (2.00) |
Apogee |
Apogee Therapeutics, Common Company Net Income Analysis
Apogee Therapeutics,'s Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Apogee Therapeutics, Net Income | (83.98 M) |
Most of Apogee Therapeutics,'s fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Apogee Therapeutics, Common is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Apogee Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Apogee Therapeutics, Common reported net income of (83.98 Million). This is 124.61% lower than that of the Biotechnology sector and 219.9% lower than that of the Health Care industry. The net income for all United States stocks is 114.71% higher than that of the company.
Apogee Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Apogee Therapeutics,'s direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Apogee Therapeutics, could also be used in its relative valuation, which is a method of valuing Apogee Therapeutics, by comparing valuation metrics of similar companies.Apogee Therapeutics, is currently under evaluation in net income category among its peers.
Apogee Therapeutics, ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Apogee Therapeutics,'s sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Apogee Therapeutics,'s managers, analysts, and investors.Environmental | Governance | Social |
Apogee Fundamentals
| Return On Equity | -0.26 | ||||
| Return On Asset | -0.19 | ||||
| Current Valuation | 1.9 B | ||||
| Shares Outstanding | 43.42 M | ||||
| Shares Owned By Insiders | 11.66 % | ||||
| Shares Owned By Institutions | 88.34 % | ||||
| Number Of Shares Shorted | 8.5 M | ||||
| Price To Book | 3.29 X | ||||
| EBITDA | (83.98 M) | ||||
| Net Income | (83.98 M) | ||||
| Total Debt | 2.03 M | ||||
| Book Value Per Share | 12.55 X | ||||
| Cash Flow From Operations | (74.76 M) | ||||
| Short Ratio | 18.70 X | ||||
| Earnings Per Share | (2.43) X | ||||
| Target Price | 92.29 | ||||
| Number Of Employees | 91 | ||||
| Market Capitalization | 2.42 B | ||||
| Total Asset | 401.4 M | ||||
| Retained Earnings | (123.77 M) | ||||
| Working Capital | 377.85 M | ||||
| Net Asset | 401.4 M |
About Apogee Therapeutics, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Apogee Therapeutics, Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Apogee Therapeutics, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Apogee Therapeutics, Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Apogee Therapeutics, is a strong investment it is important to analyze Apogee Therapeutics,'s competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Apogee Therapeutics,'s future performance. For an informed investment choice regarding Apogee Stock, refer to the following important reports:Check out Apogee Therapeutics, Piotroski F Score and Apogee Therapeutics, Altman Z Score analysis. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Apogee Therapeutics,. If investors know Apogee will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Apogee Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Apogee Therapeutics, is measured differently than its book value, which is the value of Apogee that is recorded on the company's balance sheet. Investors also form their own opinion of Apogee Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Apogee Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Apogee Therapeutics,'s market value can be influenced by many factors that don't directly affect Apogee Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Apogee Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Apogee Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Apogee Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.